Fuzionaire Diagnostics

Fuzionaire Dx is a radiopharmaceutical company. Their radiolabeling platform is designed to unlock the potential of PET to help detect and treat any disease and enhance the drug discovery process. Based on a single, catalyst-driven, disease-agnostic platform, they rapidly produce a variety of fluorine-18 radiopharmaceuticals. Their technology offers researchers and clinicians a new strategy to detect, locate, diagnose, and monitor more diseases with unprecedented precision at earlier stages. The platform is also expected to become a unique tool for drug manufacturers, providing critical in vivo pharmacological data early in the drug discovery process.